Hematopoietic Stem Cell Support in Vasculitis
NCT00278512
Terminated
The systemic vasculitis is a wide-ranging group of diseases that are characterized by the presence of blood vessel inflammation (1). Despite this common feature, each type of vasculitis has a unique variety of clinical manifestations that influences its degree of disease severity and ultimately its management. Immunosuppressive therapy forms the foundation of treatment for almost all forms of systemic vasculitis. The systemic necrotizing vasculitis (SNV) are a subset of vasculitis with signific... Read More
Gender:
ALL
Ages:
Between 16 years and 60 years
Trial Updated:
10/30/2017
Locations: Northwestern University, Feinberg School of Medicine, Chicago, Illinois
Conditions: Vasculitis
Register for Updates
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00425802
Completed
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. Also, monoclonal antibodies, such as rituximab, can find cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer ce... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/24/2017
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Leukemia, Lymphoma
Register for Updates
Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism
NCT00282412
Terminated
Rheumatoid arthritis disease is believed to be due to immune cells, cells that normally protect the body and are now causing damage to the body. Risk of death is highest in people with twenty or more joints actively involved with disease, positive rheumatoid factor, an elevated sedimentation rate (laboratory measures of active inflammation), and patients with limitation of daily activities (trouble doing simple things like opening a carton of milk). In these high risk patients, life is significa... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
10/24/2017
Locations: Northwestern University, Feinberg School of Medicine, Chicago, Illinois
Conditions: Rheumatoid Arthritis
Register for Updates
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
NCT01313884
Terminated
The outcome of patients with metastatic Ewings Sarcoma is poor with current standard of care chemotherapy, with less than 30% survival. Based on recent encouraging pediatric literature we have designed this trial to improve the outcome of patients with metastatic Ewings sarcoma using Irinotecan and Temozolomide in addition to standard chemotherapy.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
10/20/2017
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Bone Cancer, Ewing's Sarcoma
Register for Updates
DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation
NCT00083915
Completed
The purpose of this study is to find out if transplant with a new regimen of chemotherapy called DT PACE-Melphalan is better than transplant with Melphalan alone. DT-PACE refers to a chemotherapy regimen for multiple myeloma consisting of Dexamethasone, Thalidomide, Cisplatin or Platinol, Adriamycin or doxorubicin, Cyclophosphamide, and Etoposide. Another purpose of this study is to find out if there will be fewer side effects with the new regimen of DT PACE-Melphalan, compared to melphalan alon... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2017
Locations: University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide
NCT00574080
Terminated
Add three drugs, bortezomib, thalidomide, and dexamethasone (VTD) to the high dose chemotherapy regimen immediately before transplant (DPACE/Melphalan) to try to improve myeloma response and acquire longer survival for participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2017
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Register for Updates
A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
NCT01660750
Completed
This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and cyclophosphamide with dexamethasone (Car-Cy-Dex) prior to autologous stem cell transplant (ASCT) in patients with newly diagnosed transplant eligible multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2017
Locations: Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California +4 locations
Conditions: Multiple Myeloma
Register for Updates
CD123 Redirected Autologous T Cells for AML
NCT02623582
Terminated
Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART123) in Acute Myeloid Leukemia (AML) subjects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/13/2017
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Relapsed or Refractory Acute Myeloid Leukemia
Register for Updates
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
NCT01265901
Completed
The primary objective of the phase III study is to investigate whether IMA901 can prolong overall survival in patients with metastatic and/or locally advanced renal cell carcinoma (RCC) when added to standard first-line therapy with sunitinib. Secondary objectives include a subgroup analysis of overall survival in patients defined by a certain biomarker signature, the investigation of progression-free survival, best tumor response, safety, and immunological parameters.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2017
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +105 locations
Conditions: Metastatic Renal Cell Carcinoma
Register for Updates
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT00376961
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Givin... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
10/03/2017
Locations: Alaska Regional Hospital Cancer Center, Anchorage, Alaska +146 locations
Conditions: Lymphoma
Register for Updates
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
NCT00242996
Completed
RATIONALE: Giving colony-stimulating factors, such as G-CSF, monoclonal antibodies, such as rituximab, and chemotherapy, such as cyclophosphamide, helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored for peripheral stem cell transplant. Giving chemotherapy, such as carmustine, etoposide, and cyclophosphamide, before transplant stops the growth of cancer cells by stopping them from dividing or killing them. The stem cells are then returned to the p... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
09/27/2017
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Lymphoma
Register for Updates
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
NCT00281879
Terminated
RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. Giving an infusion of the donor's white blood cells (donor lymphocyte infusion) after the transplant may help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells can make an immune response against the body's normal cells. Methotrexate, cyclosporine, tacroli... Read More
Gender:
ALL
Ages:
60 years and below
Trial Updated:
09/25/2017
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Register for Updates